PVAMC
OTLK icon

PPS&V Asset Management Consultants’s Outlook Therapeutics OTLK Stock Holding History

PPS&V Asset Management Consultants’s Portfolio OTLK Stock Details OTLK Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q1 		– Sell
-2,508
Closed -$19.8K – 40
2023
Q4 		$19.8K Hold
2,508
– – 0.02% 40
2023
Q3 		$11.1K Hold
2,508
– – 0.01% 38
2023
Q2 		$87.3K Hold
2,508
– – 0.07% 38
2023
Q1 		$54.7K Hold
2,508
– – 0.05% 38
2022
Q4 		$54.2K Buy
+2,508
New +$54.6K 0.05% 36

Other funds holding OTLK

TCM
Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return
GPP
Great Point Partners Greenwich, Connecticut $435M AUM 318.81% 1-Year Est. Return
AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
SFM
Sphera Funds Management Tel Aviv, Israel $630M AUM 108.65% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
CP
Caligan Partners New York $1.5B AUM 518.95% 1-Year Est. Return
VCIM
Velan Capital Investment Management Alpharetta, Georgia $160M AUM 517.12% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
RA
Rosalind Advisors Toronto, Ontario, Canada $249M AUM 80.12% 1-Year Est. Return
SSA
Schonfeld Strategic Advisors New York $14.2B AUM 37.17% 1-Year Est. Return

PPS&V Asset Management Consultants's OTLK Position: Q1 2024 in Review

PPS&V Asset Management Consultants sold out of Outlook Therapeutics (OTLK) in Q1 2024, closing a stake of 2,508 shares — an estimated $19.8K sold.

PPS&V Asset Management Consultants first reported a position in OTLK in Q4 2022 and held it in 5 quarters. The position peaked at $87.3K in Q2 2023. 56 funds tracked by Wall St. Rank hold OTLK as of Q1 2024.

  • PPS&V Asset Management Consultants reported no remaining Outlook Therapeutics position as of Q1 2024 after selling out during the quarter.
  • PPS&V Asset Management Consultants sold 2,508 Outlook Therapeutics shares in Q1 2024, an estimated $19.8K.
  • PPS&V Asset Management Consultants first reported a position in Outlook Therapeutics in Q4 2022 and held it in 5 quarters.
  • PPS&V Asset Management Consultants's Outlook Therapeutics position peaked at $87.3K in Q2 2023.
  • 56 funds tracked by Wall St. Rank held Outlook Therapeutics as of Q1 2024.

Based on PPS&V Asset Management Consultants's 13F filing for Q1 2024, filed 10 Apr 2024.